Catalent’s ADVASEPT™ Technology is an advanced aseptic filling solution that reduces and even eliminates the main concerns associated with traditional glass vials, while reducing breakage risks and container weight for transportation and disposal.
Catalent’s ADVASEPT™ Technology is an advanced aseptic filling solution for clinical or commercial supply demands of biologics, parenteral, respiratory, and other products.
Catalent is able to leverage a superior manufacturing process that is rooted in the principles of Quality by Design to drastically reduce the risk of contamination by minimizing variables, eliminating human intervention and reducing the required class A space. The technology provides an automated container formation and closed filling process that delivers a more efficient, secure and robust injectable solution for your product.
The process utilises Blow-Fill-Seal manufacturing to produce a glass-free primary packaging container that reduces, and even eliminates, the main concerns associated with traditional glass vials, such as contamination with foreign or glass particulates and surface delamination. The ultrapure plastic design reduces breakage risks and container weight for transportation and disposal, as well as protein surface interactions. The technology is flexible, to accommodate a variety of product volumes, and can be designed to minimise headspace within the vial, reducing agitation of drug products in transit.
Catalent continues to develop and evolve ADVASEPT technology to increase the safe handling of parenteral drug products, by incorporating an optional needle-free luer lock connection fitting to containers.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.